Skip to content
Vial Announces Dosing of First Patient in Phase 1 Healthy Volunteer Trial
ABOUT US
ABOUT US
CAREERS
CONTACT US
PIPELINE
INHBE siRNA
IL-13 x TSLP
TMPRSS6
MYOSTATIN (GDF8)
α4β7 x IL-23
IL‑31 x IL‑4Rα
UPDATES
PARTNERSHIP
LICENSING
Videos
Updates
Search
Search
All Resources
Press Releases
Videos
All Resources
Press Releases
Videos
Videos
Dr. Arya M. Sharma, MD, DSc (hon), FRCPC, FCAHS, Emeritus Professor of Medicine at the University of Alberta, highlights INHBE as a promising new target for obesity, acting on both adipocytes and hepatocytes to drive fat-selective weight loss.
Videos
Dr. JiaDe Yu, Chair of Dermatology and Associate Professor at Virginia Commonwealth University School of Medicine, highlights how dual inhibition of IL-13 and TSLP could advance care for patients with atopic dermatitis, delivering stronger efficacy than targeting either pathway alone.
Load More
Videos
Dr. Arya M. Sharma, MD, DSc (hon), FRCPC, FCAHS, Emeritus Professor of Medicine at the University of Alberta, highlights INHBE as a promising new target for obesity, acting on both adipocytes and hepatocytes to drive fat-selective weight loss.
Videos
Dr. JiaDe Yu, Chair of Dermatology and Associate Professor at Virginia Commonwealth University School of Medicine, highlights how dual inhibition of IL-13 and TSLP could advance care for patients with atopic dermatitis, delivering stronger efficacy than targeting either pathway alone.
Clear search querie